What is the appropriate dosing, titration, and monitoring of cinacalcet (Sensipar) for an adult with secondary hyperparathyroidism on dialysis or hypercalcemia due to parathyroid carcinoma?

Sensipar (Cinacalcet) Dosing and Management

For secondary hyperparathyroidism in dialysis patients, start cinacalcet at 30 mg once daily with food, titrate every 2-4 weeks through sequential doses of 60,90,120, and 180 mg to target iPTH of 150-300 pg/mL, while monitoring calcium weekly and PTH every 1-4 weeks initially. For parathyroid carcinoma, start at 30 mg twice daily and titrate more aggressively every 2-4 weeks up to 90 mg four times daily to normalize serum calcium 1.

Secondary Hyperparathyroidism on Dialysis

Initial Dosing

• Starting dose: 30 mg once daily with food or shortly after a meal 1
• Tablets must be taken whole, not divided 1
• Asian populations may achieve comparable efficacy at 25-100 mg range versus Western 30-180 mg dosing 2

Titration Protocol

Titrate no more frequently than every 2-4 weeks through this sequence 1:

• 30 mg → 60 mg → 90 mg → 120 mg → 180 mg once daily
• Target iPTH: 150-300 pg/mL (consistent with K/DOQI guidelines) 3, 1
• Maximum effect onset occurs at approximately 0.46 months for PTH reduction 2

Monitoring Schedule

Initial phase (first month):

• Serum calcium and phosphorus: within 1 week of initiation or dose adjustment 1
• iPTH: 1-4 weeks after initiation or dose adjustment 1
• Measure iPTH no earlier than 12 hours after dosing 1

Maintenance phase:

• Serum calcium and phosphorus: monthly 1
• iPTH: every 1-3 months once target achieved 1

Managing Hypocalcemia (Common Pitfall)

If calcium drops below 8.4 mg/dL (occurs in 66% of patients) 1:

1. Increase calcium-based phosphate binders
2. Initiate or increase vitamin D sterols
3. Provide supplemental calcium

If calcium falls below 7.5 mg/dL or symptomatic hypocalcemia:

1. Withhold cinacalcet until calcium reaches 8.0 mg/dL and symptoms resolve 1
2. Restart at next lowest dose 1

Critical warning: Hypocalcemia risk is 7.38 times higher with cinacalcet versus placebo 4. This is the most common reason for dose adjustment or discontinuation.

Adynamic Bone Disease Risk

If iPTH falls below 100 pg/mL:

• Reduce cinacalcet dose and/or vitamin D sterols 1
• Risk of adynamic bone disease increases with prolonged suppression below this threshold 1
• In clinical trials, 11% of patients had mean iPTH <100 pg/mL during treatment 1

Parathyroid Carcinoma

Initial Dosing

• Starting dose: 30 mg twice daily 1
• More aggressive titration needed compared to secondary hyperparathyroidism

Titration Protocol

Titrate every 2-4 weeks through this sequence 1:

• 30 mg twice daily → 60 mg twice daily → 90 mg twice daily → 90 mg three or four times daily
• Target: normalize serum calcium levels 1
• In Japanese patients, maximum dose of 75 mg three times daily showed efficacy 5

Monitoring Schedule

• Serum calcium: within 1 week after initiation or dose adjustment 1
• Once maintenance dose established: every 2 months 1

Efficacy Expectations

• 62% of patients achieve ≥1 mg/dL reduction in serum calcium 6
• Greatest reductions occur in patients with highest baseline calcium 6
• Mean calcium reduction from 14.1 mg/dL to 12.4 mg/dL in responders 6
• 60% of Japanese patients achieved normocalcemia 5

Important caveat: Cinacalcet should be added to bisphosphonate or denosumab therapy when these agents alone are inadequate 7. It is not first-line monotherapy for parathyroid carcinoma.

Special Populations

Hepatic Impairment

Moderate hepatic impairment: 2.4-fold increase in exposure 1
Severe hepatic impairment: 4.2-fold increase in exposure 1

• Monitor PTH and calcium closely throughout treatment 1
• Consider lower starting doses and slower titration

Renal Impairment

• No dose adjustment necessary 1
• Pharmacokinetics unchanged by renal impairment 1

Geriatric Patients

• No dose adjustment required 1
• Age does not alter pharmacokinetics 1

Drug Interactions

Strong CYP3A4 Inhibitors

Ketoconazole, erythromycin, itraconazole cause ~2-fold increase in cinacalcet exposure 1:

• Reduce cinacalcet dose when initiating strong CYP3A4 inhibitors
• Monitor PTH and calcium closely
• Increase dose when discontinuing inhibitors

CYP2D6 Substrates

Cinacalcet is a strong CYP2D6 inhibitor 1:

• Desipramine exposure increases 3.6-fold 1
• Reduce doses of narrow therapeutic index drugs (flecainide, thioridazine, tricyclic antidepressants) 1
• Monitor for toxicity with metoprolol, carvedilol

Adverse Effects Profile

Most common (from meta-analysis of 7,446 patients) 4:

• Nausea: RR 2.05 (affects ~150 per 1,000 treated annually)
• Vomiting: RR 1.95
• Hypocalcemia: RR 7.38 (affects ~60 per 1,000 treated annually)
• Diarrhea: RR 1.15

Gastrointestinal effects may impact nutrition and quality of life 4. Consider antiemetics prophylactically in high-risk patients.

Clinical Efficacy Context

Secondary Hyperparathyroidism

Benefits:

• 43% achieve target iPTH 150-300 pg/mL versus 5% with placebo 8
• Mean PTH reduction of 43% 8
• 15% reduction in calcium-phosphorus product 8
• Prevents parathyroidectomy (RR 0.49) - approximately 3 per 1,000 patients annually 4

Limitations:

• No effect on all-cause mortality (RR 0.97) 4
• Uncertain effect on cardiovascular mortality 4
• Unclear fracture prevention benefit 4

Critical interpretation: High-quality evidence shows cinacalcet should NOT be used routinely in all dialysis patients 4. Reserve for patients with elevated PTH refractory to vitamin D and phosphate management, particularly when parathyroidectomy is contraindicated 4.

Contraindication in Specific Populations

Do NOT use cinacalcet in CKD patients not on dialysis 1:

• 80% experience calcium <8.4 mg/dL versus 5% with placebo 1
• Long-term safety and efficacy not established 1
• Higher hypocalcemia risk due to lower baseline calcium 1

Use with extreme caution in X-linked hypophosphatemia:

• Associated with severe hypocalcemia and QT prolongation 9, 10
• Grade X (strong) recommendation against routine use 9, 10

Combination Therapy Considerations

With vitamin D sterols:

• Can be used together to achieve targets 1
• Adjust vitamin D dose if hypercalcemia develops 1
• Baseline PTH and vitamin D use proportionally affect treatment response 2

With phosphate binders:

• Calcium-based binders help prevent hypocalcemia 1
• Adjust based on calcium and phosphorus levels 1

For refractory cases:

• Combination of denosumab plus cinacalcet may be effective for parathyromatosis-related hypercalcemia 11
• This is off-label use requiring careful monitoring